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Introduction
Hepatitis C virus (HCV) infection is a growing public health 
concern. Globally an estimated 180 million people, or roughly 
3% of the world’s population, are currently infected.1 The bur-
den of disease is greatest in developing countries: the highest 
reported prevalences are in China (3.2%), Egypt (22%) and 
Pakistan (4.8%).2
In light of the above, the need to improve access to care 
and treatment for patients with a chronic HCV infection is 
receiving increasing attention. A recent report by the World 
Hepatitis Alliance revealed that 80% of 135 countries surveyed 
regarded hepatitis B or C virus infection as an urgent public 
health issue.3 In 2010, the World Health Assembly adopted 
a resolution to “support or enable an integrated and cost-
effective approach to the prevention, control and management 
of viral hepatitis considering the linkages with associated 
coinfection such as HIV”.4
Most of the disease burden associated with HCV infec-
tion results from the development of chronic liver disease, 
sometimes leading to end-stage liver disease (cirrhosis), and 
standardized mortality ratios for liver-related death are 16- to 
46-fold higher in infected individuals than in the general popu-
lation.5–7 The complications of cirrhosis include liver failure, 
hepatocellular carcinoma and death.8,9 Approximately 20% 
of HCV-infected patients will experience complications.10–12 
Successful treatment can improve liver fibrosis and cirrhosis, 
help prevent hepatocellular carcinoma and even clear the 
virus.13 Treatment can also contribute to disease prevention 
by reducing the reservoir of infected individuals who can 
transmit the virus.
Despite the benefits of treatment, there is reluctance 
to making it more widely available in resource-limited 
settings because of fears that treatment success rates will 
be low and because treatment is complex, costly and pro-
duces side-effects.14 In addition, outcomes are often poor 
in patients coinfected with the human immunodeficiency 
virus (HIV).15
We performed a systematic review and meta-analysis of 
reported treatment outcomes in HCV-infected patients in 
low- and middle-income countries. The aims were to assess 
the feasibility of providing treatment for HCV infection in less 
well-resourced settings and to identify factors associated with 
successful treatment outcomes.
Methods
The PubMed and Embase databases were searched for articles 
on observational studies that reported sustained virological 
response (SVR) rates in adult patients with chronic HCV in-
fection and that were performed in a low- or middle-income 
country, as defined by The World Bank classification.16 Both 
cohort studies and case series including 10 or more patients 
were considered for inclusion. An SVR was defined as the 
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absence of detectable HCV in blood 24 
weeks after the completion of antiviral 
therapy.
The databases were searched using a 





the terms hepatitis C, HCV, treatment, 
therapy, interferon, sustained virologi-
cal response and SVR. In addition, the 
bibliographies of relevant articles were 
reviewed. Preliminary searches were 
carried out independently by two of the 
study authors, who decided whether a 
publication was eligible for inclusion 
in the systematic review by evaluating 
its title using predefined criteria. If 
there was any uncertainty, all the study 
authors were consulted to reach a con-
sensus on eligibility.
Because the aim of the systematic 
review was to describe the outcomes of 
HCV treatment administered within a 
clinical programme, we included ob-
servational cohort studies that reported 
treatment outcomes and excluded stud-
ies with an experimental design. We also 
excluded studies that reported outcomes 
in specific patient groups, such as pa-
tients with comorbid conditions, with 
prior treatment, or with known treat-
ment resistance. However, because of 
concerns about HCV infection in HIV-
infected individuals, studies on patients 
coinfected with HIV were included in 
the review.
Data extraction
Our primary outcome of interest was the 
SVR rate. Secondary outcomes included 
end-of-treatment responses, adverse 
events resulting in treatment interrup-
tion, modification or discontinuation, 
the proportion of patients lost to follow-
up, and mortality. A patient was defined 
as having an end-of-treatment response 
if HCV ribonucleic acid was undetect-
able at the completion of treatment.
Each cohort was divided into cat-
egories in accordance with the following 
discrete clinical variables: (i) whether 
standard or pegylated interferon was 
administered, irrespective of the type 
of interferon; (ii) whether fixed-dose or 
weight-adjusted ribavirin was adminis-
tered; (iii) whether treatment lasted less 
than 24 weeks or longer; (iv) whether 
fewer than or more than 50% of patients 
in the study cohort were HIV-positive 
(HIV+); (v) whether fewer than or 
more than 50% of patients in the study 
cohort were infected with genotype 1 
or 4 (these genotypes are associated 
with a poor response to treatment); and 
(vi) whether fewer than or more than 
50% of patients in the study cohort had 
bridging fibrosis, an indicator of the 
extent of liver damage, at baseline. In ad-
dition, information was also sought on 
the presence of the interleukin-28B gene 
polymorphism, which is as an important 
determinant of treatment success.
The methodological quality of the 
studies included in the systematic review 
was assessed on the basis of the study 
design (i.e. retrospective or prospective), 
the reporting of disease status at baseline, 
the proportion of patients who completed 
treatment, and consideration of potential 
confounding. Finally, information on 
sources of funding were extracted to give an 
indication of the potential replicability and 
sustainability of the treatment programme. 
Any uncertainty surrounding the data was 
resolved by contacting the study authors.
Statistical analysis
Point estimates and 95% confidence 
intervals (CIs) were derived for all out-
comes. The SVR rates were calculated 
on an intention-to-treat basis, with all 
patients who initiated therapy being 
included in the denominator of the 
calculation. The variance in the raw 
proportion was stabilized using a Free-
man–Tukey-type arcsine square-root 
transformation17 and these proportions 
were pooled using a DerSimonian–Laird 
random-effects model.18 The τ2 statistic 
was calculated to assess the proportion 
of the overall variation that was attribut-
able to between-study heterogeneity.19,20 
Since pooling proportions can yield 
high rates of heterogeneity, we explored 
the potential influence of clinical and 
programmatic covariates that had been 
identified a priori through random-
effects method-of-moments meta-
regression21 and univariate subgroup 
analyses. Subgroup analyses were used 
to assess the potential influence of the 
following covariates: treatment regimen, 
HIV status, HCV genotype, liver damage 
at baseline, level of economic develop-
ment of the study region, geographical 
location of the study region and study 
design (i.e. prospective or retrospective). 
All reported P-values are two-sided 
and significance was set at P ≤ 0.05. All 
analyses were performed using Stata ver-
sion 11 (StataCorp. LP, College Station, 
United States of America).
Results
Study characteristics
Our search found 1216 articles. After 
evaluation, 93 studies, which involved 
a total of 12 213 patients, met our inclu-
sion criteria and were carried through to 
the meta-analysis (Fig. 1). Although the 
studies covered 17 countries, some were 
more frequently represented: there were 
19 studies from Brazil, 17 from Pakistan, 
13 from Egypt, 12 from China and 10 
from India.
Around half of the studies (i.e. 
46 studies involving 5995 patients) 
included patients who were predomi-
nantly infected with HCV genotype 1 
or 4. Ten studies failed to adequately 
report on viral genotype. Patients were 
treated with ribavirin and interferon in 
86 studies, while interferon alone was 
given in 7 studies: pegylated interferon 
was administered in 52 and standard 
interferon was used in 44. The extent of 
liver damage at baseline was reported 
in 33 studies, together comprising 2407 
patients. In addition, although 54 stud-
ies gave details of patients’ HIV status, 
only 3, which included 105 patients 
in total, reported outcomes among 
HIV-infected individuals. Two studies 
included data on outcomes in patients 
with and without the interleukin-28B 
gene polymorphism.
We judged the quality of the stud-
ies included in the meta-analysis to be 
moderate. The majority (i.e. 65 studies) 
reported prospectively collected data, 72 
detailed disease progression at baseline, 
77 considered potential confounding 
factors and 89 stated that ≥ 80% of pa-
tients completed treatment.
Of the 29 studies that reported 
sources of funding, 18 were supported 
by national government funds, 4 re-
ceived pharmaceutical industry funding, 
1 was supported by an international 
research grant, 1 by a charitable grant 
and 5 stated that the study received no 
specific funding. A table summarizing 
each study’s characteristics is available 





Overall, 52% (95% CI: 48–56) of pa-
tients achieved an SVR. However, the 
between-study heterogeneity in the SVR 
rate was high (τ2: 410), as expected for 
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patients were predominantly infected 
with HCV genotype 1 or 4, the propor-
tion of patients who achieved an SVR 
ranged from 4% (95% CI: 1–9)22 to 79% 
(95% CI: 66–89)23 and the pooled pro-
portion was 49% (95% CI: 43–55). For 
studies in which patients were predomi-
nantly infected with HCV genotypes 
other than 1 or 4, the SVR rate ranged 
from 16% (95% CI: 10–24)24 to 86% 
(95% CI: 77–93)25 and the pooled pro-
portion of these patients who achieved 
an SVR was 59% (95% CI: 54–64), which 
was significantly higher than among 
patients infected with HCV genotype 
1 or 4 (P  =  0.012). Since the treatment 
duration was found to be collinear with 
viral genotype, it was not considered in 
the analysis.
Fig. 2 summarizes how the SVR 
rate was influenced by HCV treat-
ment, viral genotype, liver damage 
at baseline, HIV status, the level 
of economic development and the 
geographical location of the study 
region. Univariate meta-regression 
analysis showed that the proportion 
of patients who achieved an SVR var-
ied significantly with the formulation 
of the interferon administered (i.e. 
standard or pegylated), ribavirin use, 
viral genotype, the severity of liver 
damage at baseline, HIV status and 
the level of economic development 
of the study region (Table 1). Viral 
genotype and HIV status were still 
found to be significantly associated 
with the SVR rate on multivariate 
analysis, but other factors were not. 
Further, subgroup analyses showed 
that the best outcomes were achieved 
in studies in which patients were 
either predominantly HIV-negative 
(HIV−), predominantly infected with 
an HCV genotype other than 1 or 4, or 
treated with ribavirin. The proportion 
of patients who achieved an SVR in 
the 20 studies that included patients 
with all three of these characteristics 
ranged from 45% (95% CI: 34–55)70 to 
78% (95% CI: 61–91)71 and the pooled 
proportion was 65% (95% CI: 61–68). 
The presence of the interleukin-28B 
polymorphism was associated with a 
high SVR rate in the two studies which 
reported relevant data.26,72
End-of-treatment responses were 
recorded in 49 studies. The pooled 
estimate of the proportion of patients 
who achieved an end-of-treatment 
response was higher: (i) for those who 
were HIV− than for those who were 
HIV+, at 74% versus 52%, respectively; 
(ii) for those who received ribavirin 
than for those who did not, at 69% 
versus 51%, respectively; and (iii) for 
those who received pegylated rather 
than standard interferon, at 73% versus 
62%, respectively. Overall, 53% (95% 
CI: 47–58) of patients who achieved 
an end-of-treatment response went on 
to achieve an SVR. This rate was sig-
nificantly greater in patients who were 
treated with pegylated interferon (i.e. 
57%; 95% CI: 52–63) than in those who 
received standard interferon (i.e. 47%; 
95% CI: 38–56) and in those who were 
HIV− (i.e. 59%; 95% CI: 53–64) than in 
those who were HIV+ (i.e. 35%; 95% CI: 
30–40). However, neither viral genotype 
(P  =  0.2), ribavirin treatment (P = 0.6) 
nor liver damage at baseline (P = 0.4) 
influenced the proportion that went on 
to achieve an SVR.
Adverse events that resulted in 
treatment interruption or dose modi-
fication were reported in 16 studies 
and were experienced by 17% (95%CI: 
13–23) of patients in these studies. The 
drug regimen had no significant effect 
on the proportion of these adverse 
events. Adverse events that resulted in 
treatment termination were reported 
in 39 studies and were experienced by 
4% of patients (95% CI: 3–5). These 
adverse events were significantly more 
common in patients who were taking 
weight-adjusted ribavirin than in those 
taking fixed-dose ribavirin (4% versus 
2%, respectively; P < 0.0001).  Table 2 
lists the most serious adverse events 
that led to treatment discontinuation in 
individual studies.
Overall, 39 studies reported losses 
to follow-up. The rate was generally low 
and the pooled proportion of patients 
reported as lost to follow-up was 4% 
(95% CI: 3–4). In addition, mortality 
was also low: less than 1% (95% CI: 
0.1–1) of patients were reported to have 
died during the observation period.
Discussion
Our systematic review found many 
reports of HCV treatment programmes 
in low- and middle-income countries in-
volving substantial numbers of patients. 




Citations excluded after 
screening of titles or 
abstracts (976)








Acute HCV infection (2)
Specially selected patient cohorts (8)
Retreatment (14)
No SVR reported (12)
Citations identified by the literature search (1216)
Citations retained for detailed evaluation (240)
Studies included in the review and meta-analysis (93)
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They indicated that the programmes had 
been successful. Notably, most of the 
studies that gave information on funding 
sources reported funding from domestic 
public sources. This observation is con-
sistent with recent survey data indicating 
that partial or total government funding 
is available for hepatitis treatment in 69% 
of countries worldwide and in more than 
50% of countries in all WHO regions 
except the WHO African Region.3 We 
found that overall 52% of patients treated 
in low- and middle-income countries 
achieved an SVR, which is similar to the 
rate reported in high-income countries. 
For example, in developed countries, the 
average SVR rate observed in clinical 
trials of patients with HCV genotype 1 
infections after 48 weeks of treatment 
with pegylated interferon and weight-
adjusted ribavirin ranged from 45% to 
48%, while it ranged from 22% to 31% 
after 24 weeks of treatment.116
As found in other studies, the most 
important determinants of treatment 
success were infection with an HCV 
genotype other than 1 or 4, the absence 
of liver damage at baseline, an HIV− sta-
tus and treatment with pegylated inter-
feron and ribavirin.116 The geographical 
variations in outcomes we observed 
were probably due to a combination of 
these factors. Although, as expected, 
treatment with pegylated interferon and 
ribavirin was associated with better out-
comes than treatment with other regi-
mens, the use of weight-adjusted rather 
than fixed-dose ribavirin offered no 
observable advantage. Moreover, despite 
reports that HCV treatment is associated 
with significant side-effects, only 4% of 
patients included in our meta-analysis 
discontinued treatment because of 
adverse events. The observation that 
clinical rather than geographical factors 
were the most important determinants 
of treatment success suggests that good 
outcomes can be achieved with current 
regimens in resource-limited settings 
and offers support to calls for better ac-
cess to diagnosis and treatment in these 
settings.117
We used a broad search strategy that 
attempted to capture evidence from many 
different settings. Consequently, we were 
able to compile a large meta-analytical 
data set that enabled us to assess the 
influence on treatment success of numer-
ous patient, treatment and disease char-
acteristics. However, the way in which 
studies reported information on potential 
determinants of treatment success was 
inconsistent and limited our ability to 
assess their relative contributions. For 
example, although we identified a sub-
stantial number of studies from countries 
with a relatively high burden of both HIV 
and HCV infection, only three reported 
outcomes among patients coinfected 
with the two viruses. In addition, few 
data were available on adherence to treat-
ment, another important determinant of 
treatment success. The influence of the 
interleukin-28B gene polymorphism, 
which is also known to affect responses 
to treatment, was also poorly reported, 
probably because of limited resources. 
Future studies should report data on 
factors known to influence outcomes, 
particularly those in underrepresented 
regions, notably Africa, and in under-
represented populations, notably HIV+ 
patients and people who inject drugs.
Furthermore, the substantial het-
erogeneity in results we observed 
between studies limited the validity of 
this analysis, as it made it more difficult 
to determine the magnitude of the rela-
tive influence of individual factors on 
treatment success. In addition, we may 
have missed some studies because we 
searched a limited number of databases 
and our review excluded studies that 
reported outcomes in patients who 
were coinfected with a non-HIV agent 
that may have influenced treatment 
outcomes, such as the hepatitis B virus. 
Finally, our analysis was also limited 
by inconsistent reporting of second-
ary outcomes. Future studies should 
report rapid virological responses, 
end-of-treatment responses, adverse 
events and losses to follow-up. Data on 
rapid virological responses would help 
inform decisions on whether to shorten 
treatment.114
Given these limitations, our review 
should not be taken as representative of 
Fig. 2.  Sustained virological responsea rate in patients with a chronic hepatitis C virus 
infection in low- and middle-income countries, by treatment, disease, patient 
and study covariates





 Forest plot SVR rate (95% CI) P-valueb τ2c
Treatment
Standard interferon 44 5818 47(40–54) 0.034 533
Pegylated interferon 52 6576 56(52–61) Reference 243
Fixed-dose ribavirin 14 2473 55(43–67) 0.9 492
Weight-adjusted ribavirin 68 8564 54(51–58) Reference 216
HCV genotype
Genotype 1 or 4 46 5995 49(43–54) 0.008 427
Not genotype 1 or 4 36 4699 59(54–64) Reference 243
Liver damage at baseline
Yes2 4 2407 46(32–60) 0.2 343
No 9  1875 56(49–63) Reference 287
HIV status
HIV-positive3 105 23(15–31) <0.0001 0
HIV-negative5 1 6740 55(51–59) Reference 203
Level of economic 
developmentd
Low- or lower-middle income 30 4260 61(56–66) <0.0001 168
Upper-middle income 62 7633 48(43–53) Reference 468
WHO Region
South-East Asia Region 12 539 63(52–74) Reference 301
Eastern Mediterranean Region 35 5441 55(49–62) 0.2 491
Region of the Americas 23 3040 38(34–42) <0.0001 77
Western Pacific Region 14 1798 58(40–67) 0.6 396
European Region 7 1305 54(40–67) 0.3 314
African Region 29 0 58(35–81) 0.7 217
Percentage
CI, confidence interval; HIV, human immunodeficiency virus; HCV, hepatitis C virus; SVR, sustained 
virological response; WHO, World Health Organization.
a  A sustained virological response was defined as the absence of detectable hepatitis C virus (HCV) in 
blood 24 weeks after the completion of antiviral therapy.
b P-values were derived using the χ2 test for the difference between reference and comparison groups.
c  The Tau-squared (τ2) statistic indicates the degree to which the overall variation in the sustained 
virological response rate was attributable to between-study heterogeneity.
d The level of economic development of the study country was categorized using the World Bank 
classification.16Bull World Health Organ 2012;90:540–550 | doi:10.2471/BLT.11.097147 544
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all low- and middle-income countries. 
It does, however, illustrate the range of 
treatment outcomes that can be achieved 
in settings with limited resources.
With currently available regimens, 
the treatment success rate achievable in 
patients infected with an HCV genotype 
other than 1 and 4 is in line with or bet-
ter than the success rate achieved with 
other chronic infections that cause sub-
stantial morbidity in resource-limited 
settings, such as multidrug-resistant 
tuberculosis.118 However, currently the 
cost of treatment is a major barrier: a 48-
week course of pegylated interferon and 
ribavirin costs as much in Thailand as 
in the United Kingdom of Great Britain 
and Northern Ireland (i.e. around 17 000 
United States dollars). Treatment with 
recently approved protease inhibitors 
substantially improves success rates and 
these drugs are now the standard of care 
for patients with HCV genotype 1 infec-
tions in resource-rich settings, but they 
are even more expensive.119 In a recent 
survey in low-income countries, four 
out of five ministries of health identi-
fied the need for financial assistance to 
increase access to treatment for viral 
hepatitis as a priority.3 Future research 
Table 2.  Serious adverse events leading to treatment discontinuation in patients with a chronic hepatitis C virus infection in low- and 
middle-income countries, 1996–2011
Publication Year Country No. of 
patients 
affected
Type of event (No. of patients affected)
Sood58 2002 India 3 Psychiatric illness (2), hypotension (1)
Sood87 2006 India 3 Agitated behaviour (1), liver decompensation (2)
Gupta71 2006 India 1 Weakness (1)
Ahmed27 2011 Pakistan 14 Thrombocytopenia, ascites, depression, arthralgia, weight loss, rash, fever, hair loss, 
epistaxisa
Khan46 2009 Pakistan 12 Extreme weakness (6), severe depression (2), thyroid dysfunction (3), recurrent 
leukopenia (1)
Khokhar47 2002 Pakistan 2 Myalgia (1), psychosis (1)
Khalid45 2009 Pakistan 1 Severe depression (1)
Idrees42 2009 Pakistan 6 Psychosis (6)
Butt75 2009 Pakistan 5 Thrombocytopenia and neutropenia (2), refractory anaemia (2), ascites and hepatic 
encephalopathy (1)
Lerias de Almeida76 2009 Brazil 33 Not stated
Lerias de Almeida90 2010 Brazil 7 Not stated
Goncales78 2006 Brazil 10 Depression (6), neutropenia (2), anaemia (1), low platelet count (1)
Narciso-Schiavon81 2010 Brazil 22 Anaemia (2), thrombocytopenia (2), not stated (18)
Khattab91 2010 Egypt 4 Not stated
El Makhzangy92 2009 Egypt 2 Psychiatric disorder (1), haemolytic anaemia (1)
El-Zayadi22 1996 Egypt 8 Not stated
El-Zayadi38 2005 Egypt 4 Neutropenia (1), thyroid dysfunction (1), depression (1), neutropenia (1)
Yu111 2009 China 1 Severe anaemia (1)
Gheorghe100 2007 Romania 11 Severe psychiatric side-effects, severe haematological abnormalities, severe 
reactivation of previously controlled rheumatoid arthritis, cardiac deatha
Gheorghe99 2009 Romania 20 Severe psychiatric side-effects (2), severe haematological abnormalities (9), 
occurrence or reactivation of auto-immune disease during antiviral therapy (7), 
cardiac death (1), not stated (1)
Gheorghe98 2005 Romania 10 Severe haematological abnormalities, severe and protracted skin rash, acute 
cytomegalovirus hepatitisa
Gallegos-Orozco39 2005 Mexico 1 Thyrotoxicosis (1)
Ridruejo106 2010 Argentina 18 Not stated
Laufer104 2011 Argentina 2 Thrombocytopenia (2)
Seow107 2005 Malaysia 1 Excessive lethargy (1)
Pramoolsinsap50 1998 Thailand 3 Thrombocytopenia (2), hyperthyroidism (1)
Kalantari44 2007 Islamic 
Republic of 
Iran
2 Thrombocytopenia (1), major depression (1)
Petrenkiene49 2004 Lithuania 11 Anaemia (1), thrombocytopenia (5), irritability (1), exacerbation of concomitant 
disease (1), not stated (3)
Belhadj95 2008 Tunisia 5 Not stated
Sombie108 2011 Burkina 
Faso
2 Not stated
Njoum105 2008 Cameroon 6 Neutropenia, encephalitis, pancytopenia and thrombopeniaa
a Detailed data were not available.Bull World Health Organ 2012;90:540–550 | doi:10.2471/BLT.11.097147 546
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on barriers to obtaining medicines 
for the treatment of HCV infection in 
resource-limited settings should be 
encouraged.
New protease and polymerase in-
hibitors currently under investigation 
offer the potential for oral therapy that 
will further improve the SVR rate in 
patients with HCV infection and may 
also reduce both treatment complexity 
and adverse events.120 These drugs will 
be particularly useful in resource-lim-
ited settings where the disease burden 
is greatest. Given that HCV treatment 
can be successful in these settings, the 
early introduction of new therapies 
in countries with limited resources 
should be an important consideration 
during drug development. In the past, 
mechanisms for decreasing the cost of 
and improving access to medicines for 
chronic infections such as multidrug-
resistant tuberculosis and HIV/AIDS 
have been established; similar mecha-
nisms should be considered for HCV 
infection.
In summary, our review found 
that patients with an HCV infection 
in resource-limited settings have treat-
ment success rates similar to those in 
developed countries. This observation 
provides further justification for increas-
ing efforts to improve access to HCV 
treatment in low- and middle-income 
countries. ■
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صخلم
يفصو ليلتحو يجهنم ضارعتسا :لخدلا ةطسوتمو ةضفخنم نادلبلا في نمزلما C دبكلا باهتلا جلاع جئاتن
 C  دبكلا  باهتلا  سويرف  ىودع  جلاع  ةيلاعف  مييقت  ضرغلا
 لماوعلا ديدتحو لخدلا ةطسوتمو ةضفخنم نادلبلا في ))HCV
.ةحجانلا جئاتنلاب ةطبترلما
 جمارب تاساردل ًايفصو ًلايلتحو ًايجهنم ًاضارعتسا انيرجأ ةقيرطلا
 ةطسوتمو ةضفخنم نادلبلا في C دبكلا باهتلا سويرف جلاع
 ةميدتسم  ةيسويرف  ةباجتسا  ةيلولأا  ةجيتنلا  تناكو  .لخدلا
 للاخ نم جلاعلا جئاتنب ةطبترلما لماوعلا ديدتح متو .)SVR(
.ةيئاوشعلا راثلآل يفصولا دادترلاا ليلتح
 مت  ا ً ضيرم  12213  لوح  تانايب  لىع  ليلحتلا  لمتشا  جئاتنلا
 ةباجتسلال ليكلا لدعلما ناكو .اًدلب 17 نم ةسارد 93 في مهجاردإ
 .)56-48  :ةقثلا  لصاف  ،%  95(  %  52  ةميدتسلما  ةيسويرفلا
 ماع لكشب ينباصم ضىرم تمض يتلا تاساردلا صوصخبو
 لدعلما ناك ،4 وأ 1 ينيلجا طمنلاب C دبك باهتلا سويرف ىودعب
 :ةقثلا لصاف ،% 95( % 49 ةميدتسلما ةيسويرفلا ةباجتسلال عمجلما
 59 لدعم نع ةيربك ةجردب ًاضفخنم لدعلما اذه ناكو .)55-43
 يتلا تاساردلا في دوجولما )64-54 :ةقثلا لصاف ،% 95( %
 ىرخلأا ةينيلجا طمانلأا ىودعب ماع لكشب ينباصم ضىرم تمض
 ةحجانلا جئاتنلاب ةطبترلما لماوعلا تنمضتو .)0.012 = لماتحلاا(
 ىودعلاو  ،لوعفلما  يديدم  نييرفابيرلاو  نويرفترنلإاب  جلاعلا
 1 ينيلجا طمنلا يرغ نم C دبكلا باهتلا سويرفل ينيلجا طمنلاب
 يعانلما زوعلا سويرف ىودع دوجو مدع وأ دبكلا فلت مدعو 4 وأ
 لدعم في رثؤم فلاتخا ةظحلام متت لمو .ساسلأا طخ دنع يشربلا
 لدعلما نييرفابيرلاب جلاعلا ينب ةميدتسلما ةيسويرفلا ةباجتسلاا
 ةبسن تجتن ،ماع لكشبو .ةعرلجا تباث جلاعلا ينبو نزولا بسح
 نع ةرئاضلا ثادحلأا نم )23-13 :ةقثلا لصاف ،% 95( % 17
 لصاف ،% 95( % 4 ةبسن تجتن مانيب ةعرلجا ليدعت وأ جلاعلا عطق
.جلاعلا فاقيإ نع ثادحلأا هذه نم )5-3 :ةقثلا
 في C دبكلا باهتلا سويرف ىودع جلاع جئاتن تناك جاتنتسلاا

























Résultats du traitement de l’hépatite C chronique dans les pays à revenu faible et moyen: évaluation systématique et méta-analyse
Objectif Évaluer l’efficacité du traitement de l’infection par le virus de 
l’hépatite C (VHC) dans les pays à revenu faible et moyen et identifier 
les facteurs associés aux résultats positifs.
Méthodes Nous avons effectué une évaluation systématique et une 
méta-analyse des études sur les programmes de traitement du VHC dans 
les pays à revenu faible et moyen. Le résultat principal consistait en une 
réponse virologique soutenue (RVS). Les facteurs liés aux résultats du 
traitement ont été identifiés à l’aide d’une analyse de méta-régression 
des effets aléatoires.
Résultats L’analyse portait sur les données de 12 213 patients inclus 
dans 93 études provenant de 17 pays différents. Le taux de RVS 
général était de 52% (intervalle de confiance de 95%, IC: 48-56). 
Pour les études dans lesquelles les patients étaient principalement 
atteints par le VHC de génotype 1 ou 4, le taux de RVS groupé était Bull World Health Organ 2012;90:540–550 | doi:10.2471/BLT.11.097147 547
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de 49% (IC de 95%: 43-55). Ce taux était largement inférieur à celui 
de 59% (IC de 95%: 54-64) présenté dans les études dans lesquelles 
les patients étaient principalement atteints par d’autres génotypes 
(P = 0,012). Les facteurs liés aux résultats positifs incluaient le traitement 
à l’interféron pégylé et à la ribavirine, l’infection à un VHC de génotype 
autre que 1 ou 4 et l’absence de lésions au foie ou d’infection par le 
virus de l’immunodéficience humaine initialement. Aucune différence 
significative dans le taux de RVS n’a été observée entre les traitements 
de ribavirine adaptés au poids et ceux à dose fixe. Dans l’ensemble, 17% 
(IC de 95%: 13-23) des effets indésirables ont entraîné une interruption 
du traitement ou une modification des doses, tandis que 4% (IC de 95%: 
3-5) d’entre eux ont entraîné un abandon du traitement.
Conclusion Les résultats du traitement de l’infection du VHC dans 
les pays à revenu faible et moyen étaient similaires à ceux qui étaient 
indiqués dans les pays à revenu élevé.
Резюме
Результаты лечения хронического гепатита С в странах с низким и средним уровнем дохода: 
систематический обзор и мета-анализ
Цель Оценить эффективность лечения вируса гепатита С (ВГС) в 
странах с низким и средним уровнем дохода, а также определить 
факторы, влияющие на достижение успешных результатов.
Методы Мы провели систематический обзор и мета-анализ 
исследований, посвященных программам лечения ВГC в странах 
с низким и средним уровнем дохода. В качестве основного 
параметра оценки было выбранополучение устойчивого 
вирусологического ответа (УВО). Факторы, связанные с 
результатами лечения, идентифицировались с помощью мета-
регрессионного анализа на основе модели случайных эффектов.
Результаты Были проанализированы данные о 12 213 пациентах, 
участвовавших в 93 исследованиях в 17 странах. Общий уровень 
УВО составил 52% (доверительный интервал, ДИ 95%: 48–56). 
Для исследований, в которых пациенты были инфицированы 
преимущественно ВГС с генотипом 1 или 4, агрегированное 
значение УВО составило 49% (ДИ 95%: 43–55). Это было 
значительно ниже уровня 59% (ДИ 95%: 54–64), выявленного 
в исследованиях, в которых пациенты были инфицированы 
преимущественно другими генотипами (P = 0,012).  Факторы, 
влияющие на достижение успешных результатов, включали 
лечение пегилированным интерфероном и рибавирином, 
инфицирование генотипом, отличным от 1 и 4, а также отсутствие 
повреждения печени или вируса иммунодефицита человека на 
начальном этапе. Не наблюдалось каких-либо существенных 
различий в уровне УВО между дозировкой рибавирина в 
зависимости от массы тела и фиксированной дозировкой. В 
целом, 17% (ДИ 95%: 13–23) нежелательных реакций приводили 
к прерыванию лечения или изменению дозировки, а 4% (ДИ 95%: 
3–5) – к прекращению лечения.
Вывод Результаты лечения инфекции ВГС в странах с низким 
и средним уровнем дохода были схожи с теми, о которых 
отчитываются в странах с высоким уровнем доходов.
Resumen
Resultados del tratamiento de la hepatitis C crónica en países de ingresos medios y bajos: examen sistemático y meta-análisis
Objetivo Determinar la efectividad del tratamiento para la infección 
por el virus de la hepatitis C (VHC) en países de ingresos medios y bajos 
e identificar los factores asociados con unos resultados satisfactorios.
Métodos Realizamos un examen sistemático y un meta-análisis de 
estudios de programas de tratamiento del VHC en países de ingresos 
medios y bajos. El resultado fundamental fue una respuesta viral 
sostenida (RVS). Los factores asociados con los resultados del tratamiento 
se identificaron mediante un análisis de metarregresión de efectos 
aleatorios.
Resultados El análisis incluyó datos sobre 12 213 pacientes en 
93 estudios de 17 países. La tasa global de RVS fue del 52% (intervalo 
de confianza, IC del 95%: 48–56). Para estudios en los que los pacientes 
estaban predominantemente infectados con VHC del genotipo 
1 o 4, la tasa de RVS combinada fue del 49% (IC del 95%: 43–55). 
Esta fue significativamente menor que la tasa del 59% (IC del 95%: 
54–64) encontrada en estudios en los que los pacientes estaban 
predominantemente infectados con otros genotipos (P = 0,012). 
Los factores asociados con los resultados satisfactorios incluyeron el 
tratamiento con interferón pegilado y ribavirina, la infección del VHC 
de un genotipo distinto al 1 o al 4 y la ausencia de lesión hepática o 
de infección por el virus de la inmunodeficiencia humana en el inicio. 
No se observaron diferencias significativas en la tasa de RVS entre el 
tratamiento de ribavirina adaptado al peso del paciente y el de dosis 
fijas. En conjunto, el 17% (IC del 95%: 13–23) de los eventos adversos 
provocó la interrupción del tratamiento o la modificación de la dosis, 
mientras que el 4% (IC del 95%: 3–5) causó el abandono del tratamiento.
Conclusión Los resultados del tratamiento de la infección del VHC en 
países de ingresos bajos y medios fueron similares a los de países de 
ingresos elevados.
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